NCT01171898 2026-02-24Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)Aragon Pharmaceuticals, Inc.Phase 1/2 Completed127 enrolled 16 charts
NCT07002320 2025-12-04ASpiREInstitute of Cancer Research, United KingdomPhase 1/2 Recruiting78 enrolled